TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07110454: Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up

Sponsor: Epiminder America, Inc. · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 210 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$2,754,800

Rescue Site Savings

+$1,823,600

Unlock Full NCT07110454 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07110454 Rescue Dossier →